Sponsors (9)
The bill funds a targeted study and surveillance that could improve detection and policy for cholangiocarcinoma among Vietnam‑era veterans, at the cost of modest fiscal impact, potential resource diversion within VA/CDC, and privacy trade-offs.
Vietnam-era veterans will get improved disease surveillance and earlier detection of cholangiocarcinoma through the study and ongoing tracking, enabling more targeted VA care and better resource planning for health systems.
Congress and federal policymakers will receive concrete study results and administrative/legislative recommendations within a year, giving timely evidence to guide policy or benefits changes.
If the study prompts expanded VA benefits for cholangiocarcinoma, taxpayers could face increased federal costs for benefit payments and care.
Sharing and comparing registry data between VA and CDC could raise veterans' privacy concerns if data safeguards are not robust.
The study and ongoing tracking will require VA and CDC staff time and funding, which could divert resources from other VA programs and services.
Based on analysis of 2 sections of legislative text.
Requires the Department of Veterans Affairs, working with the CDC, to begin an epidemiological study within 120 days of enactment to measure how common cholangiocarcinoma (bile duct cancer) is among veterans who served in the Vietnam theater compared with the U.S. population. The VA must use existing cancer registries for data, report results and recommendations to Congress after the study, and provide periodic follow-up reports while continuing to track cases in its registry.
Introduced January 21, 2025 by Nicholas LaLota · Last progress April 8, 2025